Sirukumab: A novel therapy for lupus nephritis?

Uma Thanarajasingam; Timothy B. Niewold

doi:10.1517/13543784.2014.950837

Sirukumab: A novel therapy for lupus nephritis?

Uma Thanarajasingam, Timothy B. Niewold

Rheumatology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

Original language	English (US)
Pages (from-to)	1449-1455
Number of pages	7
Journal	Expert Opinion on Investigational Drugs
Volume	23
Issue number	10
DOIs	https://doi.org/10.1517/13543784.2014.950837
State	Published - Oct 1 2014

Keywords

Biologic
Human
IL-6
Lupus nephritis
Monoclonal antibody
Sirukumab
Systemic lupus erythematosus
Therapy

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.2014.950837

Cite this

@article{0bbc575461c747dda27bdd0c8c07dda5,

title = "Sirukumab: A novel therapy for lupus nephritis?",

abstract = "Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.",

keywords = "Biologic, Human, IL-6, Lupus nephritis, Monoclonal antibody, Sirukumab, Systemic lupus erythematosus, Therapy",

author = "Uma Thanarajasingam and Niewold, {Timothy B.}",

year = "2014",

month = oct,

day = "1",

doi = "10.1517/13543784.2014.950837",

language = "English (US)",

volume = "23",

pages = "1449--1455",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

TY - JOUR

T1 - Sirukumab

T2 - A novel therapy for lupus nephritis?

AU - Thanarajasingam, Uma

AU - Niewold, Timothy B.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

AB - Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

KW - Biologic

KW - Human

KW - IL-6

KW - Lupus nephritis

KW - Monoclonal antibody

KW - Sirukumab

KW - Systemic lupus erythematosus

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84907045551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907045551&partnerID=8YFLogxK

U2 - 10.1517/13543784.2014.950837

DO - 10.1517/13543784.2014.950837

M3 - Article

C2 - 25189410

AN - SCOPUS:84907045551

SN - 1354-3784

VL - 23

SP - 1449

EP - 1455

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 10

ER -

Sirukumab: A novel therapy for lupus nephritis?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this